Biologics Data Protection In Trade Agreements Becoming Key Focus For PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.